OSE Immunotherapeutics SA

ENXTPA:OSE Stock Report

Market Cap: €160.1m

OSE Immunotherapeutics Management

Management criteria checks 3/4

OSE Immunotherapeutics' CEO is Nicolas Poirier, appointed in Jan 2016, has a tenure of 9.75 years. total yearly compensation is €1.62M, comprised of 24.6% salary and 75.4% bonuses, including company stock and options. directly owns 4.93% of the company’s shares, worth €7.89M. The average tenure of the management team and the board of directors is 3.8 years and 3.3 years respectively.

Key information

Nicolas Poirier

Chief executive officer

€1.6m

Total compensation

CEO salary percentage24.65%
CEO tenure9.8yrs
CEO ownership4.9%
Management average tenure3.8yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

OSE Immunotherapeutics SA's (EPA:OSE) Shares Bounce 33% But Its Business Still Trails The Industry

Jul 30
OSE Immunotherapeutics SA's (EPA:OSE) Shares Bounce 33% But Its Business Still Trails The Industry

OSE Immunotherapeutics SA's (EPA:OSE) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

May 04
OSE Immunotherapeutics SA's (EPA:OSE) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

The Strong Earnings Posted By OSE Immunotherapeutics (EPA:OSE) Are A Good Indication Of The Strength Of The Business

Apr 05
The Strong Earnings Posted By OSE Immunotherapeutics (EPA:OSE) Are A Good Indication Of The Strength Of The Business

We Think OSE Immunotherapeutics (EPA:OSE) Can Stay On Top Of Its Debt

Apr 04
We Think OSE Immunotherapeutics (EPA:OSE) Can Stay On Top Of Its Debt

Revenues Working Against OSE Immunotherapeutics SA's (EPA:OSE) Share Price

Feb 17
Revenues Working Against OSE Immunotherapeutics SA's (EPA:OSE) Share Price

OSE Immunotherapeutics SA (EPA:OSE) Held Back By Insufficient Growth Even After Shares Climb 31%

Oct 19
OSE Immunotherapeutics SA (EPA:OSE) Held Back By Insufficient Growth Even After Shares Climb 31%

Shareholders Will Be Pleased With The Quality of OSE Immunotherapeutics' (EPA:OSE) Earnings

Oct 04
Shareholders Will Be Pleased With The Quality of OSE Immunotherapeutics' (EPA:OSE) Earnings

Would OSE Immunotherapeutics (EPA:OSE) Be Better Off With Less Debt?

May 23
Would OSE Immunotherapeutics (EPA:OSE) Be Better Off With Less Debt?

We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt

Oct 02
We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt

We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt

Apr 30
We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt

OSE Immunotherapeutics SA (EPA:OSE) Analysts Are Way More Bearish Than They Used To Be

May 11
OSE Immunotherapeutics SA (EPA:OSE) Analysts Are Way More Bearish Than They Used To Be

Is OSE Immunotherapeutics (EPA:OSE) A Risky Investment?

May 08
Is OSE Immunotherapeutics (EPA:OSE) A Risky Investment?

Imagine Holding OSE Immunotherapeutics (EPA:OSE) Shares While The Price Zoomed 322% Higher

Mar 16
Imagine Holding OSE Immunotherapeutics (EPA:OSE) Shares While The Price Zoomed 322% Higher

CEO Compensation Analysis

How has Nicolas Poirier's remuneration changed compared to OSE Immunotherapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024€2m€400k

€37m

Sep 30 2024n/an/a

€42m

Jun 30 2024n/an/a

€46m

Mar 31 2024n/an/a

€12m

Dec 31 2023€440k€300k

-€23m

Sep 30 2023n/an/a

-€25m

Jun 30 2023n/an/a

-€28m

Mar 31 2023n/an/a

-€23m

Dec 31 2022€1mn/a

-€18m

Sep 30 2022n/an/a

-€13m

Jun 30 2022n/an/a

-€7m

Mar 31 2022n/an/a

-€12m

Dec 31 2021€18kn/a

-€17m

Sep 30 2021n/an/a

-€21m

Jun 30 2021n/an/a

-€25m

Mar 31 2021n/an/a

-€21m

Dec 31 2020€19kn/a

-€17m

Sep 30 2020n/an/a

-€12m

Jun 30 2020n/an/a

-€8m

Mar 31 2020n/an/a

-€6m

Dec 31 2019€9kn/a

-€5m

Compensation vs Market: Nicolas's total compensation ($USD1.91M) is above average for companies of similar size in the French market ($USD530.00K).

Compensation vs Earnings: Nicolas's compensation has been consistent with company performance over the past year.

CEO

Nicolas Poirier (43 yo)

9.8yrs
Tenure
€1,622,966
Compensation

Dr. Nicolas Poirier, PhD, has been the Scientific Director of OSE Immunotherapeutics SA since 2016 and serves as its Director from June 26, 2019 and also serves as its General Director & Chief Executive Of...

Leadership Team

NamePositionTenureCompensationOwnership
Nicolas Poirier
General Director9.8yrs€1.62m4.93%
€ 7.9m
Anne-Laure Autret-Cornet
Administrative & Financial Director and Employee Shareholder Representative Director9.4yrs€21.34kno data
Thomas Gidoin
Chief Financial Officerless than a yearno datano data
Fiona Olivier
Chief Corporate Affairs & Investor Relations Officerless than a yearno datano data
Alexis Peyroles
Consultant3.8yrs€586.59k0.49%
€ 783.5k
Alain Chatelin
Medical Directorno datano datano data
Bérangère Vasseur
Chief Medical Officer Immuno-Oncology7.8yrsno datano data
Julien Perrier
Chief Commercial Officer6.8yrsno datano data
Linda Lebon
Chief Regulatory Officer3.8yrsno datano data
Silvia Comis
Chief Clinical & Medical Research Officer3.8yrsno datano data
Jean-Jacques Mention
Chief Business Officerno datano datano data
Sonya Montgomery
Chief Development Officerless than a yearno datano data
3.8yrs
Average Tenure
47.5yo
Average Age

Experienced Management: OSE's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Nicolas Poirier
General Director6.3yrs€1.62m4.93%
€ 7.9m
Anne-Laure Autret-Cornet
Administrative & Financial Director and Employee Shareholder Representative Director2.3yrs€21.34kno data
Maryvonne Hiance
Vice Chairwoman9.4yrs€30.00k1.66%
€ 2.7m
Bernard Malissen
Member of Scientific Advisory Board3.3yrsno datano data
Markus Cappel
Chairman of the Boardless than a yearno datano data
Sophie Brouard
Director of External Affairs & Member of the Scientific Advisory Board3.3yrs€25.71kno data
Charles Serhan
Member of Scientific Advisory Board3.3yrsno datano data
Brigitte Dreno
Independent Director8.3yrs€17.14kno data
Wolf-Herve Fridman
Chairman of the Scientific Board11.9yrsno datano data
Jennifer Wargo
Member of Scientific Advisory Board3.3yrsno datano data
Miriam Merad
Member of Scientific Advisory Board3.3yrsno datano data
Eric Leire
Independent Director2.3yrs€30.00kno data
3.3yrs
Average Tenure
64yo
Average Age

Experienced Board: OSE's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/03 15:02
End of Day Share Price 2025/10/03 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

OSE Immunotherapeutics SA is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laura RobaDegroof Petercam
David SeynnaeveDegroof Petercam
Jyoti PrakashEdison Investment Research